Effect of Adding Vildagliptin vs Glimepiride to Metformin on Inflammation's Markers in Type-2 Diabetic Patients With CAD
Status:
Completed
Trial end date:
2019-10-10
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the effect of adding Vildagliptin versus Glimepiride to
Metformin on markers of inflammation, thrombosis, and atherosclerosis in diabetic patients
with symptomatic Coronary artery diseases.
The pre-specified established biological markers of inflammation, thrombosis, and
atherosclerosis will include: Interleukin 1 beta (IL-1 beta)), hs-CRP, Atherogenic index and
coronary risk index, Lipid profile. and adiponectin levels..